<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499940</url>
  </required_header>
  <id_info>
    <org_study_id>WVU 11011</org_study_id>
    <nct_id>NCT01499940</nct_id>
  </id_info>
  <brief_title>Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway</brief_title>
  <official_title>Phase II Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through the Vitamin D Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gerald Higa, PharmD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients with cancer that are treated with a drug called oxaliplatin. This drug is used&#xD;
      with other drugs to treat cancer. The drug can cause problems with the nerves in the hands&#xD;
      and feet called peripheral neuropathy (a side effect of the drug). Peripheral neuropathy may&#xD;
      make the hands and feet feel like they are tingling, have a burning feeling, and can cause&#xD;
      pain. Almost all patients who receive oxaliplatin as part of their cancer treatment have&#xD;
      peripheral neuropathy. Patients who do have this side effect usually have to take a lower&#xD;
      dose of or stop taking the oxaliplatin even if the drug is helping their cancer.&#xD;
&#xD;
      So far there is not a lot of information about how to make this side effect better or help it&#xD;
      go away completely. There is some information that low levels of Vitamin D in the blood might&#xD;
      be linked to problems or diseases of the nervous system like multiple sclerosis or&#xD;
      Parkinson's Disease. It is even thought that Vitamin D may help protect the cells in the&#xD;
      nervous system. Because of this information, researchers want to see if giving patients&#xD;
      Vitamin D while they are receiving the drug oxaliplatin to see if it helps prevent the side&#xD;
      effect peripheral neuropathy.&#xD;
&#xD;
      Patients taking oxaliplatin who want to be in this study will take one Vitamin D capsule each&#xD;
      day while they take oxaliplatin. Being in this study will not affect how the patient's cancer&#xD;
      is treated. There are blood tests in the study to check Vitamin D levels and for a protein&#xD;
      called nerve growth factor (NGF). The study team will carefully monitor the patients for any&#xD;
      signs of oxaliplatin-related neurologic toxicity during the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin is used most frequently in patients with metastatic and early-stage colorectal&#xD;
      cancers. It has been found that in the adjuvant setting, Oxaliplatin improves both disease&#xD;
      free and overall survival. Despite these results, the use of Oxaliplatin is limited by the&#xD;
      sensory neuropathy or numbness and tingling, that occurs in 80% -90% of patients. Some of&#xD;
      these patients will develop irreversible and debilitating neuropathy, in which the drug may&#xD;
      no longer be used to treat their cancer.&#xD;
&#xD;
      It is expected that this proposed study will provide new information for the role of Vitamin&#xD;
      D in the pathogenesis of Oxaliplatin-induced neurotoxicity. The dynamic effects of Vitamin D&#xD;
      on calcium and nerve growth factor plus the now recognized state of subclinical Vitamin D&#xD;
      deficiency are compelling pieces of evidence that indicate this hormone may be in a pivotal&#xD;
      position in the multifactorial pathogenesis of neurotoxic reactions induced by Oxaliplatin.&#xD;
      The specific aim of the study is to determine the neuroprotective effects of Vitamin D.&#xD;
&#xD;
      Patients will receive Oxaliplatin at a dose of 80 mg/m2 at a physician determined frequency&#xD;
      appropriate for the underlying malignancy, which can be any histological diagnosis of a&#xD;
      malignant solid neoplasm involving the GI tract not restricted to the colon, rectum and&#xD;
      esophagus. Blood will be collected to monitor the level of Vitamin D and nerve growth factor&#xD;
      (NGF) at specific time points. Vitamin D levels will be checked once a month and NGF levels&#xD;
      will be checked bi-weekly. These blood samples will be collected at the same time of the&#xD;
      patients routine blood draws. Patients will take one capsule containing 2000 IUs of Vitamin&#xD;
      D3 daily, beginning up to 7 days prior to the first dose of Oxaliplatin. Vitamin D3 will be&#xD;
      provided to patients as long as they remain on the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Research cancelled - no funding identified.&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Peripheral Neurotoxic Reactions</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>NCI CTCAE Version 4.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Neurotoxicity</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 2000 IU/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.</description>
    <arm_group_label>Vitamin D3 2000 IU/day</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologic diagnosis of a malignant solid neoplasm involving the&#xD;
             gastrointestinal tract not necessarily restricted to the colon, rectum, and esophagus,&#xD;
&#xD;
          -  Will receive oxaliplatin-based chemotherapy for the first time (previous treatment&#xD;
             with non-oxaliplatin-based chemotherapy does not preclude eligibility),&#xD;
&#xD;
          -  Have disease of any stage and will be treated according to established standards,&#xD;
&#xD;
          -  Have a performance status (ECOG) of 2 or less,&#xD;
&#xD;
          -  Have intact organ function as determined by laboratory tests of the kidney, liver, and&#xD;
             bone marrow deemed appropriate to receive cytotoxic chemotherapy,&#xD;
&#xD;
          -  Are 18 years of age or older, and&#xD;
&#xD;
          -  Have signed a consent and information form to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant (subjects of childbearing age will have a pregnancy test performed),&#xD;
&#xD;
          -  Are taking calcitriol or have vitamin D levels that are &gt;100 ng/dL,&#xD;
&#xD;
          -  Are receiving medication for seizures, or&#xD;
&#xD;
          -  Have pre-existing peripheral neuropathy grade &gt;1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Higa, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University Hospitals Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kim JS, Ryu SY, Yun I, Kim WJ, Lee KS, Park JW, Kim YI. 1alpha,25-Dihydroxyvitamin D(3) Protects Dopaminergic Neurons in Rodent Models of Parkinson's Disease through Inhibition of Microglial Activation. J Clin Neurol. 2006 Dec;2(4):252-7. doi: 10.3988/jcn.2006.2.4.252. Epub 2006 Dec 20.</citation>
    <PMID>20396528</PMID>
  </reference>
  <reference>
    <citation>Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, Borlongan CV, Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001 Jun 15;904(1):67-75.</citation>
    <PMID>11516412</PMID>
  </reference>
  <reference>
    <citation>Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18-28. Review. Erratum in: Am J Clin Nutr. 2006 Nov;84(5):1253. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. Am J Clin Nutr. 2007 Sep;86(3):809. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.</citation>
    <PMID>16825677</PMID>
  </reference>
  <reference>
    <citation>Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review.</citation>
    <PMID>17634462</PMID>
  </reference>
  <reference>
    <citation>Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1706S-9S. doi: 10.1093/ajcn/80.6.1706S. Review.</citation>
    <PMID>15585791</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <results_first_submitted>August 9, 2021</results_first_submitted>
  <results_first_submitted_qc>August 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2021</results_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Gerald Higa, PharmD.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>peripheral neuropathy</keyword>
  <keyword>vitamin D status</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3 2000 IU/Day</title>
          <description>Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study&#xD;
Vitamin D3: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was withdrawn before completion.</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3 2000 IU/Day</title>
          <description>Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study&#xD;
Vitamin D3: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Peripheral Neurotoxic Reactions</title>
        <description>NCI CTCAE Version 4.0</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU/Day</title>
            <description>Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study&#xD;
Vitamin D3: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peripheral Neurotoxic Reactions</title>
          <description>NCI CTCAE Version 4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3 2000 IU/Day</title>
          <description>Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study&#xD;
Vitamin D3: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerald Higa, PharmD</name_or_title>
      <organization>West Virginia Universtiy</organization>
      <phone>(304) 293-1461</phone>
      <email>ghiga@hsc.wvu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

